GoHealth price target lowered to $20 from $25 at Noble Capital

Noble Capital analyst Patrick McCann lowered the firm’s price target on GoHealth (GOCO) to $20 from $25 and keeps an Outperform rating on the shares after the company reported Q2 revenue below the firm’s forecast. The firm now expects Q3 revenue to moderate to $100M, down from its prior estimate, and it trimmed both revenue and adjusted EBITDA estimates for 2025, but it continues to anticipate revenue growth and margin expansion in 2026.